Identification and functional characterization of key biomarkers in diffuse large B-cell lymphoma: emphasis on STYX as a prognostic marker and therapeutic target

Abstract Diffuse large B-cell lymphoma (DLBC) is the most common subtype of non-Hodgkin lymphoma, characterized by its aggressive nature and poor prognosis in advanced stages. Despite advances in treatment, the molecular mechanisms driving DLBC progression remain incompletely understood, necessitati...

Full description

Saved in:
Bibliographic Details
Main Authors: Junaid Abid, Mahmood Basil A. Al-Rawi, Ahmad Mahmood, An Li, Tiemin Jiang
Format: Article
Language:English
Published: BMC 2025-03-01
Series:Hereditas
Subjects:
Online Access:https://doi.org/10.1186/s41065-025-00411-w
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850172723661111296
author Junaid Abid
Mahmood Basil A. Al-Rawi
Ahmad Mahmood
An Li
Tiemin Jiang
author_facet Junaid Abid
Mahmood Basil A. Al-Rawi
Ahmad Mahmood
An Li
Tiemin Jiang
author_sort Junaid Abid
collection DOAJ
description Abstract Diffuse large B-cell lymphoma (DLBC) is the most common subtype of non-Hodgkin lymphoma, characterized by its aggressive nature and poor prognosis in advanced stages. Despite advances in treatment, the molecular mechanisms driving DLBC progression remain incompletely understood, necessitating the identification of novel biomarkers for diagnosis and prognosis. In this study, we analyzed two publicly available datasets (GSE32018 and GSE56315) from the Gene Expression Omnibus database (GEO) to identify overlapping differentially expressed genes (DEGs). Later on, a comprehensive in silico and in vitro methodology was adopted to decipher the role of identify DEGs in DLBC. DEGs analysis of GSE32018 and GSE56315 datasets identified five overlapping gene: SP3, CSNK1A1, STYX, SIRT5, and MGEA5. Expression validation using the GEPIA2 database confirmed the upregulation of SP3, CSNK1A1, STYX, and SIRT5, and the downregulation of MGEA5 in DLBC tissues compared to normal controls. Furthermore, mutational analysis revealed that CSNK1A1 was the only gene among these DEGs to exhibit mutations, with a 2.7% mutation frequency in DLBC patients. Methylation analysis highlighted a negative correlation between DEGs methylation levels and mRNA expression, while survival analysis identified high STYX expression as significantly associated with poorer overall survival in DLBC patients. Functional assays demonstrated that STYX knockdown in U2932 cells led to reduced cell proliferation, colony formation, and enhanced wound healing, indicating STYX’s pivotal role in DLBC cell survival and migration. Additionally, gene enrichment analysis revealed the involvement of these DEGs in key biological processes, including intracellular trafficking and myeloid progenitor cell differentiation. These findings emphasize the potential of SP3, CSNK1A1, STYX, SIRT5, and MGEA5 as biomarkers and therapeutic targets in DLBC, particularly highlighting STYX as a promising prognostic marker and potential target for therapeutic intervention.
format Article
id doaj-art-7e34a650f45f42e1a8a804f0029f0245
institution OA Journals
issn 1601-5223
language English
publishDate 2025-03-01
publisher BMC
record_format Article
series Hereditas
spelling doaj-art-7e34a650f45f42e1a8a804f0029f02452025-08-20T02:20:01ZengBMCHereditas1601-52232025-03-01162111710.1186/s41065-025-00411-wIdentification and functional characterization of key biomarkers in diffuse large B-cell lymphoma: emphasis on STYX as a prognostic marker and therapeutic targetJunaid Abid0Mahmood Basil A. Al-Rawi1Ahmad Mahmood2An Li3Tiemin Jiang4State Key Laboratory of Food Nutrition and Safety, College of Biotechnology, Tianjin University of Science and TechnologyDepartment of Optometry, College of Applied Medical Sciences, King Saud UniversityDepartment of Hepatobiliary & Hydatid Diseases, Digestive & Vascular Surgery Center, The First Affiliated Hospital of Xinjiang Medical UniversityDepartment of Hepatobiliary & Hydatid Diseases, Digestive & Vascular Surgery Center, The First Affiliated Hospital of Xinjiang Medical UniversityDepartment of Hepatobiliary & Hydatid Diseases, Digestive & Vascular Surgery Center, The First Affiliated Hospital of Xinjiang Medical UniversityAbstract Diffuse large B-cell lymphoma (DLBC) is the most common subtype of non-Hodgkin lymphoma, characterized by its aggressive nature and poor prognosis in advanced stages. Despite advances in treatment, the molecular mechanisms driving DLBC progression remain incompletely understood, necessitating the identification of novel biomarkers for diagnosis and prognosis. In this study, we analyzed two publicly available datasets (GSE32018 and GSE56315) from the Gene Expression Omnibus database (GEO) to identify overlapping differentially expressed genes (DEGs). Later on, a comprehensive in silico and in vitro methodology was adopted to decipher the role of identify DEGs in DLBC. DEGs analysis of GSE32018 and GSE56315 datasets identified five overlapping gene: SP3, CSNK1A1, STYX, SIRT5, and MGEA5. Expression validation using the GEPIA2 database confirmed the upregulation of SP3, CSNK1A1, STYX, and SIRT5, and the downregulation of MGEA5 in DLBC tissues compared to normal controls. Furthermore, mutational analysis revealed that CSNK1A1 was the only gene among these DEGs to exhibit mutations, with a 2.7% mutation frequency in DLBC patients. Methylation analysis highlighted a negative correlation between DEGs methylation levels and mRNA expression, while survival analysis identified high STYX expression as significantly associated with poorer overall survival in DLBC patients. Functional assays demonstrated that STYX knockdown in U2932 cells led to reduced cell proliferation, colony formation, and enhanced wound healing, indicating STYX’s pivotal role in DLBC cell survival and migration. Additionally, gene enrichment analysis revealed the involvement of these DEGs in key biological processes, including intracellular trafficking and myeloid progenitor cell differentiation. These findings emphasize the potential of SP3, CSNK1A1, STYX, SIRT5, and MGEA5 as biomarkers and therapeutic targets in DLBC, particularly highlighting STYX as a promising prognostic marker and potential target for therapeutic intervention.https://doi.org/10.1186/s41065-025-00411-wDLBCDiagnosisPrognosis: TreatmentTherapeutic target
spellingShingle Junaid Abid
Mahmood Basil A. Al-Rawi
Ahmad Mahmood
An Li
Tiemin Jiang
Identification and functional characterization of key biomarkers in diffuse large B-cell lymphoma: emphasis on STYX as a prognostic marker and therapeutic target
Hereditas
DLBC
Diagnosis
Prognosis: Treatment
Therapeutic target
title Identification and functional characterization of key biomarkers in diffuse large B-cell lymphoma: emphasis on STYX as a prognostic marker and therapeutic target
title_full Identification and functional characterization of key biomarkers in diffuse large B-cell lymphoma: emphasis on STYX as a prognostic marker and therapeutic target
title_fullStr Identification and functional characterization of key biomarkers in diffuse large B-cell lymphoma: emphasis on STYX as a prognostic marker and therapeutic target
title_full_unstemmed Identification and functional characterization of key biomarkers in diffuse large B-cell lymphoma: emphasis on STYX as a prognostic marker and therapeutic target
title_short Identification and functional characterization of key biomarkers in diffuse large B-cell lymphoma: emphasis on STYX as a prognostic marker and therapeutic target
title_sort identification and functional characterization of key biomarkers in diffuse large b cell lymphoma emphasis on styx as a prognostic marker and therapeutic target
topic DLBC
Diagnosis
Prognosis: Treatment
Therapeutic target
url https://doi.org/10.1186/s41065-025-00411-w
work_keys_str_mv AT junaidabid identificationandfunctionalcharacterizationofkeybiomarkersindiffuselargebcelllymphomaemphasisonstyxasaprognosticmarkerandtherapeutictarget
AT mahmoodbasilaalrawi identificationandfunctionalcharacterizationofkeybiomarkersindiffuselargebcelllymphomaemphasisonstyxasaprognosticmarkerandtherapeutictarget
AT ahmadmahmood identificationandfunctionalcharacterizationofkeybiomarkersindiffuselargebcelllymphomaemphasisonstyxasaprognosticmarkerandtherapeutictarget
AT anli identificationandfunctionalcharacterizationofkeybiomarkersindiffuselargebcelllymphomaemphasisonstyxasaprognosticmarkerandtherapeutictarget
AT tieminjiang identificationandfunctionalcharacterizationofkeybiomarkersindiffuselargebcelllymphomaemphasisonstyxasaprognosticmarkerandtherapeutictarget